Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP08 in MTAP-deleted Advanced Solid Tumors
NCT06973863Phase 1Recruiting
- Sponsor
- PharmaEngine, Inc.
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PEP08 in solid tumor, sponsored by PharmaEngine, Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at 2 years, Number of Participants Experiencing Serious Adverse Events at 2 years and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
PEP08
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06973863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973863.